Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75

BACKGROUND: Hormone-refractory prostate cancer (HRPC) is characterized by poor response to chemotherapy and high mortality, particularly among African American men when compared to other racial/ethnic groups. It is generally accepted that docetaxel, the standard of care for chemotherapy of HRPC, pri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mediavilla-Varela, Melanie, Pacheco, Fabio J, Almaguel, Frankis, Perez, Jossymar, Sahakian, Eva, Daniels, Tracy R, Leoh, Lai Sum, Padilla, Amelia, Wall, Nathan R, Lilly, Michael B, De Leon, Marino, Casiano, Carlos A
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2009
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2741463/
https://ncbi.nlm.nih.gov/pubmed/19715609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-8-68
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars